MEDCast Podcast Por MJH Life Sciences arte de portada

MEDCast

MEDCast

De: MJH Life Sciences
Escúchala gratis

Acerca de esta escucha

 MEDCast is a healthcare program brought to you by http://HCPLive.com that features leading medical experts who discuss a range topic within a particular condition or medical disorder.© Ciencia Ciencias Biológicas Enfermedades Físicas Historia Natural Hygiene & Healthy Living Naturaleza y Ecología
Episodios
  • Real-World Treatment Strategies Using Next-Generation Therapies for Neovascular AMD and DME

    Real-World Treatment Strategies Using Next-Generation Therapies for Neovascular AMD and DME
    May 28 2025
    Ehsan Rahimy, MD; David G. Miller, MD, Michael Klufas, MD, discusses how real-world treatment strategies for neovascular AMD and DME with next-generation anti-VEGF therapies differ from clinical trials, including individualized loading dose approaches, extension interval considerations, and the challenges of balancing durability with appropriate monitoring.
    Más Menos
    37 m
  • Drying, Durability, and Disease Control: Evolving Metrics of Anti-VEGF Success in Retinal Diseases

    Drying, Durability, and Disease Control: Evolving Metrics of Anti-VEGF Success in Retinal Diseases
    May 28 2025
    Ehsan Rahimy, MD; David G. Miller, MD, Esther Kim, MD, discusses how achieving retinal drying through anti-VEGF therapies remains a critical marker of treatment success in retinal diseases like AMD and DME, while highlighting the benefits of newer agents like aflibercept 8mg and faricimab for providing better durability and sustained disease control with reduced treatment burden.
    Más Menos
    35 m
  • Real-World Treatment Strategies Using Next-Generation Therapies for Neovascular AMD and DME

    Real-World Treatment Strategies Using Next-Generation Therapies for Neovascular AMD and DME
    May 28 2025
    Ehsan Rahimy, MD; David G. Miller, MD, Michael Klufas, MD, discusses how real-world treatment strategies for neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME) with next-generation anti-VEGF therapies differ from clinical trials, including individualized loading dose approaches, extension interval considerations, and the challenges of balancing durability with appropriate monitoring.
    Más Menos
    37 m
adbl_web_global_use_to_activate_T1_webcro805_stickypopup
Todavía no hay opiniones